Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568134 · ClinicalTrials.gov registry record
Alternate Measures of Glucose During OGTT Testing for CFRD
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 14
- Enrollment target
NCT05568134: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT05568134 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05568134 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
Although early detection and treatment of cystic fibrosis-related diabetes (CFRD) can lead to significant clinical improvements and prolong life, rates of screening are poor likely due to the burdensome nature of oral glucose tolerance testing (OGTT). The investigators propose to assess the feasibility and accuracy of two screening tools, continuous glucose monitoring (CGM) and a home OGTT kit (GTT@home). If this pilot study reveals acceptable accuracy of either device, this study will allow for future studies exploring home-based OGTT screening.
Primary Outcome
Differences in fasting glucose will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose.
Interventions
- DIAGNOSTIC_TEST Oral glucose tolerance test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2024-12-13 |
What the finished NCT05568134 record still lists
NCT05568134 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Oral glucose tolerance test is the first listed.
NCT05568134 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05568134 about?
NCT05568134 is a clinical study titled "Alternate Measures of Glucose During OGTT Testing for CFRD". Although early detection and treatment of cystic fibrosis-related diabetes (CFRD) can lead to significant clinical improvements and prolong life, rates of screening are poor likely due to the burdensome nature of oral glucose tolerance testing (OGTT). The investigators propose to assess the feasibil...
What is the current status of trial NCT05568134?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2023-07-17. Estimated completion is 2024-12-13.
What interventions are being tested in trial NCT05568134?
The interventions under investigation include: Oral glucose tolerance test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05568134?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy